查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1937737

2026-2034年全球甲癣治疗市场规模、份额、趋势和成长分析报告

Global Onychomycosis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计甲癣治疗市场将从 2025 年的 57.8 亿美元成长到 2034 年的 125.1 亿美元，2026 年至 2034 年的复合年增长率为 8.97%。

受真菌性甲癣感染疾病率上升和人们对现有治疗方案认知度提高的推动，甲癣治疗市场预计将迎来显着增长。甲癣的特征是甲床及周围组织感染，影响相当一部分人群，造成不适和美观问题。随着医疗服务提供者和患者都认识到有效治疗的重要性，对创新治疗方法的需求预计将会增加。该市场正朝着更有效、更人性化的治疗方法转变，包括局部抗真菌药物、口服药物和雷射疗法。

除了传统治疗方法外，灰指甲治疗市场也受益于药物製剂技术和给药系统的进步。能够增强抗真菌药物渗透到甲母质的新型製剂备受关注，从而提高了治疗效果并缩短了疗程。此外，针对感染多个方面的联合治疗的开发正成为一种很有前景的方法，为患者提供更全面的解决方案。随着研究的深入和新的治疗标靶及作用机制的揭示，甲癣治疗市场预计将持续成长，为患者提供更多有效的治疗选择。

此外，对预防保健和病患教育的日益重视正在重塑甲癣的治疗模式。医疗服务提供者强调早期诊断和介入的重要性，并致力于教育患者正确的足部卫生和指甲护理方法。随着患者对未经治疗的真菌感染疾病风险有了更深入的了解，这种积极主动的治疗方法可能会增加对治疗方案的需求。随着甲癣治疗市场的不断发展，创新的治疗方法组合、加强患者教育以及注重预防将在应对这种常见疾病带来的挑战方面发挥关键作用。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球甲癣治疗市场：依治疗类型划分

  • 市场分析、洞察与预测
  • 药物
  • 雷射
  • 动态疗法

第五章：全球甲癣治疗市场：依适应症划分

  • 市场分析、洞察与预测
  • 远端甲下甲癣
  • 白色浅层甲癣
  • 近端甲下甲癣
  • 念珠菌性甲癣
  • 全甲癣

第六章：全球甲癣治疗市场：依年龄组别划分

  • 市场分析、洞察与预测
  • 0-18岁
  • 18至39岁
  • 40至64岁
  • 65岁或以上

第七章 全球甲癣治疗市场：依性别划分

  • 市场分析、洞察与预测
  • 男性
  • 女士

第八章：全球甲癣治疗市场：依分销管道划分

  • 市场分析、洞察与预测
  • 向机构销售
  • 零售销售

第九章 全球甲癣治疗市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十一章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Teva Pharmaceutical Industries Ltd
    • Sanofi SA
    • Medimetriks Pharmaceuticals Inc
    • Galderma
    • Johnson & Johnson
    • Novartis AG
    • Moberg Pharma AB
    • Cardinal Health Inc
    • Pfizer Inc
    • Almirall SA
    • Bayer AG
    • Viatris Inc
    • GlaxoSmithKline Plc
    • Cipla Ltd
    • Dr. Reddy'S Laboratories Ltd
简介目录
Product Code: VMR11215983

The Onychomycosis Treatment Market size is expected to reach USD 12.51 Billion in 2034 from USD 5.78 Billion (2025) growing at a CAGR of 8.97% during 2026-2034.

The onychomycosis treatment market is poised for significant growth, driven by the increasing prevalence of fungal nail infections and the rising awareness of available treatment options. Onychomycosis, characterized by the infection of the nail bed and surrounding tissues, affects a substantial portion of the population, leading to discomfort and aesthetic concerns. As healthcare providers and patients alike recognize the importance of effective treatment, the demand for innovative therapies is expected to rise. This market is witnessing a shift towards more effective and patient-friendly treatment modalities, including topical antifungals, oral medications, and laser therapies.

In addition to traditional treatment options, the onychomycosis treatment market is benefiting from advancements in drug formulation and delivery systems. Novel formulations that enhance the penetration of antifungal agents into the nail matrix are gaining traction, improving treatment efficacy and reducing the duration of therapy. Furthermore, the development of combination therapies that target multiple aspects of the infection is emerging as a promising approach, offering patients a more comprehensive solution. As research continues to unveil new therapeutic targets and mechanisms of action, the onychomycosis treatment market is expected to expand, providing patients with a wider array of effective treatment options.

Moreover, the increasing focus on preventive care and patient education is shaping the onychomycosis treatment landscape. Healthcare providers are emphasizing the importance of early diagnosis and intervention, as well as educating patients about proper foot hygiene and nail care practices. This proactive approach is likely to drive demand for treatment options, as patients become more informed about the risks associated with untreated fungal infections. As the onychomycosis treatment market continues to evolve, the combination of innovative therapies, enhanced patient education, and a growing emphasis on prevention will play a crucial role in addressing the challenges posed by this common condition.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

  • Drugs
  • Lasers
  • Photodynamic Therapy

By Disease Indication

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

By Age Group

  • 0 to 18 Years
  • 18 to 39 Years
  • 40 to 64 Years
  • 65 Years & Above

By Gender

  • Male
  • Female

By Distribution Channel

  • Institutional Sales
  • Retail Sales

COMPANIES PROFILED

  • Teva Pharmaceutical Industries Ltd, Sanofi SA, Medimetriks Pharmaceuticals Inc, Galderma, Johnson Johnson, Novartis AG, Moberg Pharma AB, Cardinal Health Inc, Pfizer Inc, Almirall SA, Bayer AG, Viatris Inc, GlaxoSmithKline plc, Cipla Ltd, Dr Reddys Laboratories Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Lasers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Photodynamic Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Disease Indication
  • 5.2. Distal Subungual Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. White Superficial Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Proximal Subungual Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Candidal Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Total Dystrophic Onychomycosis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Age Group
  • 6.2. 0 to 18 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. 18 to 39 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. 40 to 64 Years Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. 65 Years & Above Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY GENDER 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Gender
  • 7.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Institutional Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Retail Sales Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Treatment Type
    • 9.2.2 By Disease Indication
    • 9.2.3 By Age Group
    • 9.2.4 By Gender
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Treatment Type
    • 9.3.2 By Disease Indication
    • 9.3.3 By Age Group
    • 9.3.4 By Gender
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Treatment Type
    • 9.4.2 By Disease Indication
    • 9.4.3 By Age Group
    • 9.4.4 By Gender
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Treatment Type
    • 9.5.2 By Disease Indication
    • 9.5.3 By Age Group
    • 9.5.4 By Gender
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Treatment Type
    • 9.6.2 By Disease Indication
    • 9.6.3 By Age Group
    • 9.6.4 By Gender
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ONYCHOMYCOSIS TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Teva Pharmaceutical Industries Ltd
    • 11.2.2 Sanofi S.A
    • 11.2.3 Medimetriks Pharmaceuticals Inc
    • 11.2.4 Galderma
    • 11.2.5 Johnson & Johnson
    • 11.2.6 Novartis AG
    • 11.2.7 Moberg Pharma AB
    • 11.2.8 Cardinal Health Inc
    • 11.2.9 Pfizer Inc
    • 11.2.10 Almirall S.A
    • 11.2.11 Bayer AG
    • 11.2.12 Viatris Inc
    • 11.2.13 GlaxoSmithKline Plc
    • 11.2.14 Cipla Ltd
    • 11.2.15 Dr. Reddy'S Laboratories Ltd